Edwards Lifesciences Corporation (EW)
USD 67.07
(-2.8%)
USD 67.07
(-2.8%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -449.1 Million USD | -477.99% |
| 2022 | -77.7 Million USD | 54.96% |
| 2021 | -172.5 Million USD | 64.67% |
| 2020 | -488.3 Million USD | 2.4% |
| 2019 | -500.3 Million USD | -315.88% |
| 2018 | -120.3 Million USD | -155.16% |
| 2017 | 218.1 Million USD | 302.32% |
| 2016 | -107.8 Million USD | 9.03% |
| 2015 | -118.5 Million USD | -112.75% |
| 2014 | -55.7 Million USD | -132.25% |
| 2013 | 172.7 Million USD | 242.02% |
| 2012 | -121.6 Million USD | -484.62% |
| 2011 | -20.8 Million USD | 94.13% |
| 2010 | -354.3 Million USD | -45.32% |
| 2009 | -243.8 Million USD | -464.35% |
| 2008 | -43.2 Million USD | -161.8% |
| 2007 | 69.9 Million USD | 31.64% |
| 2006 | 53.1 Million USD | -61.38% |
| 2005 | 137.5 Million USD | -36.98% |
| 2004 | 218.2 Million USD | 12.07% |
| 2003 | 194.7 Million USD | -7.86% |
| 2002 | 211.3 Million USD | -19.66% |
| 2001 | 263 Million USD | -34.25% |
| 2000 | 400 Million USD | 0.0% |
| 1999 | - USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -955 Million USD | -81.77% |
| 2024 Q1 | -525.4 Million USD | -16.99% |
| 2023 Q4 | -449.1 Million USD | 37.54% |
| 2023 Q1 | -184.7 Million USD | -137.71% |
| 2023 Q2 | -358.1 Million USD | -93.88% |
| 2023 Q3 | -719 Million USD | -100.78% |
| 2023 FY | -449.1 Million USD | -477.99% |
| 2022 Q4 | -77.7 Million USD | 86.15% |
| 2022 Q3 | -561 Million USD | -8.87% |
| 2022 Q1 | -342.7 Million USD | -98.67% |
| 2022 Q2 | -515.3 Million USD | -50.36% |
| 2022 FY | -77.7 Million USD | 54.96% |
| 2021 Q2 | -628.6 Million USD | -29.5% |
| 2021 Q4 | -172.5 Million USD | 79.04% |
| 2021 FY | -172.5 Million USD | 64.67% |
| 2021 Q1 | -485.4 Million USD | 0.59% |
| 2021 Q3 | -822.8 Million USD | -30.89% |
| 2020 Q1 | 12.3 Million USD | 102.46% |
| 2020 Q2 | -219 Million USD | -1880.49% |
| 2020 FY | -488.3 Million USD | 2.4% |
| 2020 Q4 | -488.3 Million USD | -46.24% |
| 2020 Q3 | -333.9 Million USD | -52.47% |
| 2019 Q1 | -43 Million USD | 64.26% |
| 2019 Q3 | -515.9 Million USD | -781.88% |
| 2019 FY | -500.3 Million USD | -315.88% |
| 2019 Q4 | -500.3 Million USD | 3.02% |
| 2019 Q2 | -58.5 Million USD | -36.05% |
| 2018 Q1 | -172.4 Million USD | -179.05% |
| 2018 FY | -120.3 Million USD | -155.16% |
| 2018 Q4 | -120.3 Million USD | -77.43% |
| 2018 Q2 | -33.3 Million USD | 80.68% |
| 2018 Q3 | -67.8 Million USD | -103.6% |
| 2017 Q2 | 508.6 Million USD | 1678.32% |
| 2017 FY | 218.1 Million USD | 302.32% |
| 2017 Q4 | 218.1 Million USD | -45.97% |
| 2017 Q3 | 403.7 Million USD | -20.63% |
| 2017 Q1 | 28.6 Million USD | 126.53% |
| 2016 Q3 | -44.4 Million USD | -119.09% |
| 2016 Q1 | 100.8 Million USD | 185.06% |
| 2016 Q4 | -107.8 Million USD | -142.79% |
| 2016 FY | -107.8 Million USD | 9.03% |
| 2016 Q2 | 232.6 Million USD | 130.75% |
| 2015 Q3 | -41.2 Million USD | -1625.93% |
| 2015 Q1 | 145.7 Million USD | 361.58% |
| 2015 FY | -118.5 Million USD | -112.75% |
| 2015 Q2 | 2.7 Million USD | -98.15% |
| 2015 Q4 | -118.5 Million USD | -187.62% |
| 2014 Q3 | 192.3 Million USD | 93.46% |
| 2014 Q1 | 429.7 Million USD | 148.81% |
| 2014 Q2 | 99.4 Million USD | -76.87% |
| 2014 FY | -55.7 Million USD | -132.25% |
| 2014 Q4 | -55.7 Million USD | -128.97% |
| 2013 Q2 | -145.4 Million USD | 30.36% |
| 2013 Q3 | 61.1 Million USD | 142.02% |
| 2013 Q4 | 172.7 Million USD | 182.65% |
| 2013 FY | 172.7 Million USD | 242.02% |
| 2013 Q1 | -208.8 Million USD | -71.71% |
| 2012 Q4 | -121.6 Million USD | 6.75% |
| 2012 FY | -121.6 Million USD | -484.62% |
| 2012 Q3 | -130.4 Million USD | -9.4% |
| 2012 Q2 | -119.2 Million USD | -251.62% |
| 2012 Q1 | -33.9 Million USD | -62.98% |
| 2011 FY | -20.8 Million USD | 94.13% |
| 2011 Q4 | -20.8 Million USD | 92.47% |
| 2011 Q3 | -276.1 Million USD | 5.9% |
| 2011 Q2 | -293.4 Million USD | -3.2% |
| 2011 Q1 | -284.3 Million USD | 19.76% |
| 2010 FY | -354.3 Million USD | -45.32% |
| 2010 Q2 | -142.8 Million USD | 25.59% |
| 2010 Q4 | -354.3 Million USD | -36.06% |
| 2010 Q3 | -260.4 Million USD | -82.35% |
| 2010 Q1 | -191.9 Million USD | 21.29% |
| 2009 Q4 | -243.8 Million USD | -31.57% |
| 2009 Q3 | -185.3 Million USD | -167.77% |
| 2009 Q1 | -23.7 Million USD | 45.14% |
| 2009 Q2 | -69.2 Million USD | -191.98% |
| 2009 FY | -243.8 Million USD | -464.35% |
| 2008 FY | -43.2 Million USD | -161.8% |
| 2008 Q1 | 50 Million USD | -28.47% |
| 2008 Q2 | -46.5 Million USD | -193.0% |
| 2008 Q3 | 400 Thousand USD | 100.86% |
| 2008 Q4 | -43.2 Million USD | -10900.0% |
| 2007 Q4 | 69.9 Million USD | 96.9% |
| 2007 Q1 | 44.3 Million USD | -16.57% |
| 2007 Q2 | 42.7 Million USD | -3.61% |
| 2007 Q3 | 35.5 Million USD | -16.86% |
| 2007 FY | 69.9 Million USD | 31.64% |
| 2006 Q3 | 101.7 Million USD | -9.6% |
| 2006 FY | 53.1 Million USD | -61.38% |
| 2006 Q4 | 53.1 Million USD | -47.79% |
| 2006 Q2 | 112.5 Million USD | 12.5% |
| 2006 Q1 | 100 Million USD | -27.27% |
| 2005 Q2 | 173.5 Million USD | -14.62% |
| 2005 Q4 | 137.5 Million USD | -15.9% |
| 2005 Q3 | 163.5 Million USD | -5.76% |
| 2005 FY | 137.5 Million USD | -36.98% |
| 2005 Q1 | 203.2 Million USD | -6.87% |
| 2004 Q1 | 296.6 Million USD | 52.34% |
| 2004 Q2 | 272.8 Million USD | -8.02% |
| 2004 Q3 | 238.2 Million USD | -12.68% |
| 2004 Q4 | 218.2 Million USD | -8.4% |
| 2004 FY | 218.2 Million USD | 12.07% |
| 2003 Q4 | 194.7 Million USD | -23.59% |
| 2003 Q1 | 247.1 Million USD | 16.94% |
| 2003 Q2 | 256.6 Million USD | 3.84% |
| 2003 FY | 194.7 Million USD | -7.86% |
| 2003 Q3 | 254.8 Million USD | -0.7% |
| 2002 Q3 | 240.9 Million USD | -8.05% |
| 2002 Q4 | 211.3 Million USD | -12.29% |
| 2002 Q2 | 262 Million USD | -0.87% |
| 2002 Q1 | 264.3 Million USD | 0.49% |
| 2002 FY | 211.3 Million USD | -19.66% |
| 2001 FY | 263 Million USD | -34.25% |
| 2001 Q1 | 396.5 Million USD | -0.88% |
| 2001 Q4 | 263 Million USD | -16.72% |
| 2001 Q3 | 315.8 Million USD | -3.31% |
| 2001 Q2 | 326.6 Million USD | -17.63% |
| 2000 FY | 400 Million USD | 0.0% |
| 2000 Q4 | 400 Million USD | -17.63% |
| 2000 Q3 | 485.6 Million USD | -8.2% |
| 2000 Q2 | 529 Million USD | 1.15% |
| 2000 Q1 | 523 Million USD | 0.0% |
| 1999 Q4 | - USD | 0.0% |
| 1999 FY | - USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Abbott Laboratories | 8.97 Billion USD | 105.003% |
| Allurion Technologies Inc. | 3.82 Million USD | 11856.545% |
| Artivion, Inc. | 300.4 Million USD | 249.5% |
| Avanos Medical, Inc. | 121.4 Million USD | 469.934% |
| Butterfly Network, Inc. | -109.6 Million USD | -309.729% |
| Butterfly Network, Inc. | -109.6 Million USD | -309.729% |
| Bio-Rad Laboratories, Inc. | 1 Billion USD | 144.824% |
| Boston Scientific Corporation | 8.62 Billion USD | 105.206% |
| CONMED Corporation | 966.95 Million USD | 146.445% |
| Paragon 28, Inc. | 36.39 Million USD | 1334.096% |
| Glaukos Corporation | 290.27 Million USD | 254.717% |
| Globus Medical, Inc. | 53.11 Million USD | 945.572% |
| Inspire Medical Systems, Inc. | -160.69 Million USD | -179.48% |
| Integer Holdings Corporation | 1.01 Billion USD | 144.147% |
| Medtronic plc | 24.76 Billion USD | 101.814% |
| Myomo, Inc. | -6.27 Million USD | -7062.676% |
| Nevro Corp. | 117.61 Million USD | 481.855% |
| Owlet, Inc. | -1.34 Million USD | -33389.958% |
| Penumbra, Inc. | 66.85 Million USD | 771.732% |
| Vicarious Surgical Inc. | -37.99 Million USD | -1082.153% |
| Smith & Nephew plc | 2.78 Billion USD | 116.143% |
| Sonendo, Inc. | 26.34 Million USD | 1804.882% |
| STERIS plc | 3.17 Billion USD | 114.14% |
| Stryker Corporation | 10.02 Billion USD | 104.48% |
| Vapotherm, Inc. | 102.66 Million USD | 537.434% |
| Zimmer Biomet Holdings, Inc. | 5.57 Billion USD | 108.049% |